Overview

Clinical Evaluation of BW430C in Epilepsy

Status:
Completed

Trial end date:
2009-03-26

Target enrollment:

Participant gender:

Summary

To evaluate safety information of BW430C when administered using the lower starting doses and slower dose escalations as recommended Global Data Sheet

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Lamotrigine